Kariann Abbate, MD
Cardiovascular Disease · Ridgewood, NJNPI 1548429582
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $74,458 of the $91,826 with a category attached, or 81.1%. 21 manufacturers reported payments, led by Boehringer Ingelheim at 42.0% of the total. Reporting peaked in 2020 at $21,678 and has fallen 68.7% since, to $6,785 in 2025. Among cardiovascular disease clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 200 payments — averaging $459.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$39K
- Pfizer$28K
- Lilly USA, LLC$14K
- Novartis$8K
- Abbott$1K
- Actelion Pharmaceuticals US, Inc.$191
- plus $1K from 15 others
Across 30 payments — averaging $9617.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Endotronix, Inc.$160K
- Novartis$50K
- AstraZeneca$36K
- Sanofi US Services Inc.$28K
- Alnylam Pharmaceuticals Inc.$14K
What the payments were for
- Consulting fees$9,50910%
- Speaking & faculty fees$74,45881%
- Travel & lodging$2,6763%
- Food & beverage$5,1046%
- Education$800%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 49 | $38,524 |
| Pfizer | 28 | $27,850 |
| Lilly USA, LLC | 15 | $14,451 |
| Novartis | 13 | $8,370 |
| Abbott | 32 | $1,185 |
| Actelion Pharmaceuticals US, Inc. | 3 | $191 |
| Biomerieux Inc | 1 | $168 |
| Alnylam Pharmaceuticals Inc. | 2 | $129 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $127 |
| Abiomed | 4 | $123 |
| AstraZeneca | 3 | $113 |
| Irhythm Technologies, Inc. | 6 | $102 |
| Amgen | 6 | $87 |
| United Therapeutics Corporation | 10 | $86 |
| Johnson & Johnson | 7 | $83 |
| Daiichi Sankyo Inc. | 5 | $70 |
| Boston Scientific | 2 | $70 |
| E.r. Squibb & Sons, L.L.C. | 3 | $44 |
| Bayer | 2 | $26 |
| Merck | 1 | $15 |
| Medtronic | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$52,552
- VYNDAQEL$27,724
- ENTRESTO$8,282
- CARDIOMEMS$414
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$134
How this compares
$91,826 in reported general payments places this provider in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 307 | $8,833,265 |
| CamzyosMavacamten | 63 | $514,654 |
| JardianceEmpagliflozin | 394 | $495,283 |
| EntrestoSacubitril/Valsartan | 327 | $494,035 |
| Orenitram ErTreprostinil Diolamine | 25 | $274,024 |
| FarxigaDapagliflozin Propanediol | 244 | $272,434 |
| EliquisApixaban | 233 | $272,405 |
| XareltoRivaroxaban | 81 | $103,975 |
| OzempicSemaglutide | 45 | $48,633 |
| Repatha SureclickEvolocumab | 29 | $31,627 |
| Ambrisentan | 13 | $27,267 |
| Praluent PenAlirocumab | 23 | $24,492 |
| MounjaroTirzepatide | 20 | $20,002 |
| WegovySemaglutide | 11 | $14,357 |
| VerquvoVericiguat | 14 | $13,269 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $27,850 | $9,105,670540 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $44 | $514,65463 claims |
| Boehringer IngelheimJardiance | $38,524 | $495,283394 claims |
| NovartisEntresto | $8,370 | $494,035327 claims |
| AstraZenecaFarxiga | $113 | $272,434244 claims |
| Johnson & JohnsonXarelto | $83 | $103,97581 claims |
| Lilly USA, LLCMounjaro | $14,451 | $20,00220 claims |
| MerckVerquvo | $15 | $13,26914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in Ridgewood
- Marc CohenNewark$762K
- Peter FarrugiaColts Neck$600K
- Felix Dailey-SterlingGuttenberg$568K
- Ramzan ZakirNew Brunswick$342K
- Richard KovachBrowns Mills$300K
- Andrea RussoCamden$293K
- John KostisNew Brunswick$225K
- Dilip ViswanathHaddon Heights$167K
- David PowellSpringfield$162K
- Fadi ChaabanWest Orange$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.